90 related articles for article (PubMed ID: 15486447)
1. Can erythropoietin therapy improve survival?
Glaspy J; Dunst J
Oncology; 2004; 67 Suppl 1():5-11. PubMed ID: 15486447
[TBL] [Abstract][Full Text] [Related]
2. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.
Aapro M; San Miguel J
Oncology; 2004; 67 Suppl 1():17-22. PubMed ID: 15486449
[TBL] [Abstract][Full Text] [Related]
3. Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models.
Boogaerts M; Mittelman M; Vaupel P
Oncology; 2005; 69 Suppl 2():22-30. PubMed ID: 16244507
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
Pujade-Lauraine E; Topham C
Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
[TBL] [Abstract][Full Text] [Related]
5. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
[TBL] [Abstract][Full Text] [Related]
6. Optimising anaemia management with epoetin beta.
Reed N; Morère JF
Oncology; 2004; 67 Suppl 1():12-6. PubMed ID: 15486448
[TBL] [Abstract][Full Text] [Related]
7. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke M; Weingart O; Kluge S; Piper M; Rades D; Steensma DP; Djulbegovic B; Fey MF; Ray-Coquard I; Machtay M; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
Lancet; 2009 May; 373(9674):1532-42. PubMed ID: 19410717
[TBL] [Abstract][Full Text] [Related]
9. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
10. Epoetin beta therapy in patients with solid tumours.
Pronzato P; Jassem J; Mayordomo J
Crit Rev Oncol Hematol; 2006 Apr; 58(1):46-52. PubMed ID: 16169242
[TBL] [Abstract][Full Text] [Related]
11. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study.
Osterborg A; Brandberg Y; Hedenus M
Br J Haematol; 2005 Apr; 129(2):206-9. PubMed ID: 15813848
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cancer-related anemia with epoetin alfa: a review.
Ferrario E; Ferrari L; Bidoli P; De Candis D; Del Vecchio M; De Dosso S; Buzzoni R; Bajetta E
Cancer Treat Rev; 2004 Oct; 30(6):563-75. PubMed ID: 15325036
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients.
Aapro M; Scherhag A; Burger HU
Br J Cancer; 2008 Jul; 99(1):14-22. PubMed ID: 18542079
[TBL] [Abstract][Full Text] [Related]
14. Role of epoetin in the management of anaemia in patients with lung cancer.
Morère JF
Lung Cancer; 2004 Nov; 46(2):149-56. PubMed ID: 15474662
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
16. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
[TBL] [Abstract][Full Text] [Related]
17. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
18. Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis.
Boogaerts M; Oberhoff C; Ten Bokkel Huinink W; Nowrousian MR; Hayward CR; Burger HU
Anticancer Res; 2006; 26(1B):479-84. PubMed ID: 16739308
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
Bohlius J; Wilson J; Seidenfeld J; Piper M; Schwarzer G; Sandercock J; Trelle S; Weingart O; Bayliss S; Djulbegovic B; Bennett CL; Langensiepen S; Hyde C; Engert A
J Natl Cancer Inst; 2006 May; 98(10):708-14. PubMed ID: 16705125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
